What is new in the treatment of gynaecological cancer including ovarian cancer, cervical cancer and endometrial cancer? Read our gynaecological cancer blog and learn more about the latest advancements in the treatment female cancers.

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

 

  • On June 13, 2018, the FDA approved bevacizumab (AvastinⓇ, Genentech, Inc.) in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab for use after surgical resection in patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

 

  • On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.
cancer awareness improves outcome medipaper medical communications

Cancer symptom awareness linked to survival

Increased cancer awareness improves survival, according to a recent study by Cancer Research UK (CRUK) published in the British Journal of Cancer (BJC). The researchers matched cancer symptom awareness from a population-based survey in over 35,000 people across the UK with the cancer registry.

2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

In women with stage IIIC or IV ovarian cancer, primary cytoreductive surgery (PCS) may be preferred when there is a high chance to achieve cytoreduction to <1 cm with acceptable morbidity. This was concluded by an expert panel who published clinical guidelines in the Journal of Clinical Oncology (JCO) this week.

ASCO 2016 Palbociclib Data MediPaper Medical Communications

ASCO16 palbociclib (Ibrance©) Data

There is no excerpt because this is a protected post.